Brooks Laboratories is currently trading at Rs. 146.40, up by 8.65 points or 6.28 % from its previous closing of Rs. 137.75 on the BSE.
The scrip opened at Rs. 138.00 and has touched a high and low of Rs. 149.65 and Rs. 138.00 respectively. So far 90493 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 194.40 on 01-Nov-2016 and a 52 week low of Rs. 72.00 on 24-Jun-2016.
Last one week high and low of the scrip stood at Rs. 149.65 and Rs. 137.00 respectively. The current market cap of the company is Rs. 235.84 crore.
The promoters holding in the company stood at 60.62%, while Institutions and Non-Institutions held 0.28% and 39.11% respectively.
Brooks Laboratories has commenced commercial production at its New Manufacturing Unit-II, Vadodara, Gujarat. The company’s Vadodra facility had received manufacturing licence from Commissioner of Food & Drugs Control Administration, Gandhinagar last year, valid for the period of 5 years from August 16, 2016 to August 15, 2021.
Brooks Laboratories is a Research and Development driven Pharmaceutical manufacturing company, in last 6 years company has successfully established itself as a reputed Contract Manufacturing company for latest molecules in Injectables and Clavulanic Acid range in Tablets and Dry Syrups.